What men should know about the US government’s latest move on testosterone therapy

Key Points:

• The US Department of Health and Human Services (HHS) is requesting updates to testosterone replacement therapy labels to remove statements that safety and effectiveness are unestablished in age-related low testosterone and to revise warnings on prostate cancer and enlarged prostate risks.
• New research, including a large clinical study, indicates no significant increase in cardiovascular events or prostate cancer risk for men undergoing testosterone therapy, prompting HHS to propose narrower and more evidence-based label warnings.
• Experts emphasize that testosterone therapy remains a medical treatment requiring proper diagnosis, symptom evaluation, and ongoing monitoring, cautioning against indiscriminate use despite the label changes.
• The proposed revisions aim to improve patient and physician information, potentially easing access to testosterone therapy for men with genuinely low testosterone confirmed by symptoms and testing.
• While testosterone therapy benefits include improved libido, mood, energy, and muscle strength, potential side effects such as blood clots, breast tissue enlargement, and sperm suppression warrant careful medical oversight.